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REMINISCENCES:
MY FORTY-YEAR ROMANCE WITH MALARIA
G. Robert Coatney
5012 Wickford Way, NE
Dunwoody, Georgia 30338

Armed with this new parchment, I learned of an opening
in the biology department at Nebraska Wesleyan University.
After a conference with Dr. Claude Shirk, chairman of the
department, I was offered the position and went there as an
associate professor. My teaching duties were less than arduous;
research was encouraged. In that atmosphere I expected to
continue for an extended period. However, the depression
which struck the midwest in 1932 soon saw the university in
financial straits augmented by the failure of the Peters Trust
Company in Omaha, where most of the university's endowment funds were on deposit. Our salaries were reduced by one
half and for a period of five months we received no money.

Prologue
Looking back some 55 years since beginning my graduate
studies, I have come to appreciate my good fortune: (1) to
have inaugurated and carried out, over a period of some 35
years, a three-pronged research program (birds, simians, and
man) against the world's most important infectious diseasemalaria -and during two-thirds of that time, carrying worrisome administrative responsibilities; (2) to have participated
in national and international efforts towards alleviation and
control of that disease; (3) to have had a remarkable group
of professional and subprofessional people who shared all
kinds of problems; (4) to have received full support of my
scientific efforts from the Directors of the National Institutes
of Health, and last, but not least; (5) to have a wife who accepted my sometimes extended peregrinations, here and
abroad, necessitated by my commitment to the problem of
malaria. A reporter might ask, "How did a native Nebraskan,
brought up with winter's snow and hot dry summers choose a
tropical disease career?"

t

t

Luckily, a position opened at the Peru State Teachers College for which I applied and was hired. The college was established to train teachers for the Nebraska schools-hardly an
atmosphere for a research-minded associate professor of biology. As it turned out, there were compensations.
My studies involving H. columbae had whetted my interest in true malaria. At that time there was a broad interest in
avian malarias but in-depth studies were limited to infections
in the canary, which carried only a small amount of blood.
This could be overcome with a malaria in a larger bird. Peru
was located in a major flyway, and non-migratory birds were
all about. One of them might be carrying a true malaria that
would grow well in a larger bird attuned to laboratory conditions-a chicken or the common pigeon. I decided to study
the bird parasites of that bird population with one object
only: to find that parasite!

t

After receIvmg the B.A. degree from the Grand Island
Baptist College, an M.A. from the University of Nebraska, and
a teaching interlude, I contacted Dr. E. R. Becker of Iowa
State University about studying with him for the Ph.D. He
invited me to visit him and during our conversation he asked
me if I had a problem in mind or if he should select one. I
wanted to work on blood protozoa and suggested studying the
relapse phenomenon in Haemoproteus columbae, sometimes
referred to as pigeon malaria. He approved the problem, and
I won the degree.

During the next four years I described and named some
15 new species of protozoan blood parasites, but the prize was
missing-no true malaria. Owls, crows, magpies, and other
5

6 G. R. Coatney
birds, carrying protozoan blood parasites, were kept caged in
the laboratory and, as a sideline, so to speak, their infections
were treated using the then available antimalarial drugs. These
initial studies in chemotherapy were reported in several short
papers, but I attached no particular significance to them. As it
turned out, those preliminary studies pointed the way for my
subsequent career.
Among the male members of the Peru faculty I was an
oddity. I didn't play golf, I didn't hunt, and I didn't follow the
fate of the athletic teams. All I did was teach, roam the woods,
and work in the laboratory. According to my lights, the elusive malaria parasite would not be found on the golf course.
Mourning doves nested on the campus and each summer
no malaria parasites were found in their blood. In 1937, however, a nestling was found with a true malaria. It was identified
as Plasmodium relictum With that "find" the paramount question was: would it grow in the chicken, other doves, or in the
pigeon? Before those questions could be answered, the same
species was found in a young pigeon taken from a nest under
the wheel-house of the college observatory. Were they the
same parasite? They were, as determined by cross infection
experiments. In the pigeon the parasite produced a fulminating
infection, even death. I had found the long-sought malaria
parasite!
I reported finding this "new" parasite at the fall meeting
of the American Society of Parasitologists, was congratulated
on my good fortune, and had numerous requests to share the
parasite with other investigators. I was not anxious to do so
until I had time to study it myself. This reluctance was understood by other investigators.
In early 1938, I received a letter from Dr. L. L. Williams,
in charge of malaria research for the U.S. Public Health Service, asking me if I would share my new parasite for extended
studies by the Public Health Service. It took me less than five
seconds to make up my mind about that. In my reply, I told
Dr. Williams that I had spent almost five years in search of that
parasite and if the Public Health Service wanted it they could
have it but they would have to take me too. If the ploy
worked I would be in full-time research.
After a series of negotiations and an interview in Washington, D.C., I was offered an appointment to the research
staff of the Williams Malaria Research Laboratory located at
the South Carolina State Hospital in Columbia. The malariainfected pigeons and the Coatney family, which now included
our four-year-old daughter, moved to Columbia.
When I reported for work there I met Dr. Martin Young
who, I learned later, had called Dr. Williams's attention to the
new pigeon malaria. Martin was engaged in studies dealing with

the biology and mosquito transmission of human malarias,
especially vivax and malariae, used by the medical staff for
treating central nervous system syphilis Oues nervosa). My
pigeon malaria studies moved ahead, but I lost no time in joining Martin in cooperative studies dealing with the human
malarias.
Early in 1938 the Surgeon General of the Public Health
Service (PHS) saw that war was imminent. If it came, American soldiers would have to fight in highly malarious areas of
the world, and quinine was the only drug then available for
its treatment. In order to try and improve that situation, he
initiated a program at the National Institutes of Health (NIH), '
under the direction of Dr. Lyndon Small, for the synthesis of
potential antimalarial compounds. These new compounds
would have to be tested initially against malarias in lower
animals. That part of the program called for someone with
drug-testing experience. A survey of the PHS personnel found
only one person with such experience-myself. As a result, I
was transferred to the NIH to set up such a program. That
move brought the family, which now included our two-yearold son, into the Washington, D.C., area which was our home
for the next 25 years.
The Department of Agriculture, for obvious reasons, had
barred the importation of Plasmodium gallinaceum, a malaria
parasite of chickens, but now, with war on the horizon, they
relented. As a consequence, I chose to use day-old chicks and
the gallinaceum parasite in evaluating new potential drugs.
The chemists had several compounds ready for testing, but my
procedure for their evaluation failed to satisfy a certain medical officer, who had control of the program. I am sure he was
qualified as a physician but, in my opinion, he was not a qualified experimental scientist. I refused to modify the program
and notified the director that I was ready to go back to South
Carolina. The impasse was settled by my being given sole
responsibility for the testing program.
Under an increased staff, a goodly number of compounds
were tested, none of which showed promise, until we tested
NIH 204, a phenanthrene amino alcohol. It was vastly superior
to quinine against P. gallinaceum in the chicks, but would it
work in man? The answer might be found at the St. Elizabeth's Hospital in Washington, D.C. The physicians there used
vivax malaria in treating luetics. When their patient had experienced the required treatment, the disease was terminated
with quinine. Why not test the effectiveness of our new drugs,
like NIH 204, in terminating those infections? If the trial drug
reduced or terminated the infection, we would have a lead, Of
a new drug, for further tests. I could see no difficulty in PHS
physicians working with physicians at St. Elizabeth's Hospital.
The problem was that my staff did not include a physician.
Where was I to get one with a flair for research to evaluate,
NIH 204 or other test drugs? I appealed to Dr. Henry Sebrell,
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my institute chief, for help. A few days later he told me about
a young M.D. who wanted to join the PHS but was then working for a master's degree in bacteriology at Johns Hopkins University. I went over his Curriculum Vitae and immediately
asked that he be assigned to me at the NIH. Dr. Clark Cooper
joined my staff on 13 December 1941, six days after Pearl
Harbor. We worked as a team for the next eight years.
Arrangements were made quickly with the St. Elizabeth's
staff, and Cooper took over the testing of NIH 204. It proved
to be an excellent drug, but certain side effects prevented its
general use. He then tested a whole series of compounds of
similar structure, but each of them exhibited the same limitations. It was obvious that we would have to move in a different chemical direction.
A National Malaria Program had been organized by the
Committee on Medical Research under the Office of Scientific
Research and Development and its activities, on a nationwide
basis, had progressed to where test compounds were coming to
us from other laboratories. The testing of those compounds, as
well as our own, soon exhausted the supply of available mental
hospital patients. With that avenue cut off, another source of
human test subjects had to be found.
Cooper and I were discussing this sorry state of affairs in
my office one afternoon when we were joined by Dr. David
Ruhe who had recently joined our staff. Dave listened to the
discussion for a time and then said, "Chief, have you ever
thought of using prisoner volunteers?" I was struck by the idea
and decided to investigate the possibility at once.
The PHS supplies physicians for the Federal Prison Service and Dr. Marion King was the Medical Director. My course
of action was-go to your friends first. I went to see Dr. King
the very next morning and explained the situation to him.
There was a war on and a pressing need for new and better
drugs for the treatment of malaria. Could it be arranged so
that potentially effective drugs could be tested in prisoner
volunteers? Dr. King knew and approved of our work but
made it clear that using malaria for treating lues in mental
patients was an acceptable practice; employing prison volunteers for testing new drugs was quite another matter. I fully
appreciated his position. He was being asked to approve a program contrary to accepted medical practice. After a time he
agreed to endorse the program but made it clear that final
approval rested with the director, James V. Bennett. Fortunately, the director's daughter was one of my technicians, and
I hoped that might contribute to a favorable decision. When
we saw Mr. Bennet I laid the problem before him stressing the
fact that after Pearl Harbor the Japanese had cut off our
quinine supply, our stockpile was low, and the United States
needed effective new drugs for the treatment of malaria. He
listened carefully and after some time he turned to Dr. King

and said, "Marion, what do you think of the idea?" His reply
was that "If Dr. Coatney is to be in charge, I'm for it." Mr.
Bennett then wanted to consider the best place for the project.
I suggested the prison in Atlanta, Georgia, because it was close
to Milledgeville, Georgia, and to Columbia, South Carolina,
where Drs. Geoffrey Jeffery and Martin Young of the PHS
could easily supply infected mosquitoes for the project. Also,
Atlanta was easy for me to get to from Washington, and the
prison population should supply ample volunteers. Mr. Bennett
was quick to point out that Atlanta was hardly a minimum
security prison. He finally agreed that Atlanta was the best
place under the circumstances and to make our work easier he
called Mr. Sanford, the warden at Atlanta Prison, and told him
that he had approved a project which Dr. King and I would
present to him in a day or two.
Dr. King and I went to Atlanta and found Mr. Sanford far
from pleased with the proposed drug-testing project. He had a
contract for making mattresses for the army and mail bags for
the post office which yielded Prison Industries about $2 million
per year. In his light, he had reason to see us gone. I pointed
out to the warden that there was a war on and that $2 million
was a mere pittance in terms of the war effort and the crying
need for better antimalarial drugs. He finally agreed and invited me to return in a few days to present the project to the
inmate popUlation. When I next visited Atlanta, I took Dr.
Ruhe with me. The warden brought the men together in the
Great Hall of the prison with its catwalk near the ceiling and
guards with rifles. It goes without saying that I was not exactly
calm and collected under those conditions. The warden gave a
short talk and then turned the meeting over to me. I explained
the need for new antimalarial drugs for the armed forces and
the need for volunteers in assessing the effectiveness of the
new drugs.
I made it doubly clear that participants would have to be
of military age; in excellent physical condition; be willing to
accept infection with malaria, either by mosquito bite or by
blood in inoculation; and to accept medication and routine
tests as required. Each volunteer would have to agree to stay
with the project for a period of six months. At the end of that
period he would receive an honorarium of $50 (later raised to
$250) and six months would be taken off his sentence. In
addition, he would receive an attractive certificate signed by
the Surgeon General of the PHS and other dignitaries certifying as to his participation in a research study with broad significance to mankind. I was careful to ~oint out that many of
them would be sick and some so sick that they would wish
they had never heard of us and the "drug-testing program. I
went on to say that there was little likelihood of a fatal outcome and that our physicians would take care of all their
medical problems.
With that coverage of the program, I invited those who
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might like to take part in the program to meet me at the foot
of the steps. I stepped down onto the floor and the men came
forward like a wave. One fellow said to me, "Doc, did you say
that all our medical problems would be handled by your
doctors?" I replied that that was exactly what I had said and
the man on his left, Dr. Ruhe, would do exactly that. The
questioner turned to those behind him and said, "Boys, let's
go." They were with us! I am proud to say that was the only
time we asked for volunteers. Over the years the project spoke
for itself in enlisting more than one thousand volunteers from
that institution.
With the support of the warden and the inmates, the way
was cleared for remodeling the hospital to accommodate us
and for enlisting a complete staff. It was not until St. Patrick's
Day 1944 that the first 15 volunteers were infected with vivax
malaria following the bites of infected mosquitoes. It was my
privilege to take part in applying infected mosquitoes on that
historic occasion. I say "historic" because not only was this the
only country in the world where prisoner participation in such a
study was permitted, encouraged, and sanctioned by law, but
what makes it stand out even more is that it was only the second time in the history of the United States that prisoner volunteers took part in solving an important medical problem.
Let us turn back for a moment to the first of these volunteer studies. Alex St. Martin was shot in the left breast and
stomach in 1823. Dr. William Beaumont, serving in the Michigan Territory, dressed the wound which, due to adhesions,
failed to heal properly, allowing access to the stomach. Alex
was unable to work and became Beaumont's body servant.
With Alex's permission, Dr. Beaumont began the earliest
extended studies of the physiology of digestion in 1825. The
idea of participation in medical problems then lay fallow until
1915, a span of 90 years, when Dr. Joseph Goldberger, a PHS
medical officer working in Mississippi, employed 11 prisoner
volunteers in solving the cause of pellagra, at that time the
scourge of the south. The volunteers who participated in that
important study were promptly released from prison, but their
contribution was forgotten. The governor was berated by the
public and the Mississippi medical profession for allowing their
participation. Goldberger went on to receive many honors, but
his landmark was pellagra. Again, the idea of prisoner volunteer participation in solving a medical problem lay fallow, this
time for 29 years, to be broken on 17 March 1944 as mentioned earlier.
We have not forgotten the outstanding results, to be delineated later, of the volunteer studies begun in 1944, but we
seem to have forgotten that it was prisoner volunteers who
made the results possible. At this writing, prisoners in the
United States are not permitted to participate in studies aimed
at solving medical problems, suits in our courts to the contrary
notwithstanding. But now back to the main theme.

The effectiveness of test compounds was measured in
terms of their quinine equivalent against St. Elizabeth's vivax
malaria. As a consequence our initial work included intensive
studies of the biology of the parasite and the effectiveness of
quinine against it. With that basic information, evaluation of
several groups of drugs, including a series of 4-aminoquinolines,
got underway. Among that assemblage was SN-7618, now
known as chloroquine, which proved to be an outstanding
drug. It gave complete suppression of the disease, when taken
once weekly, and was highly effective as a therapeutic agent.
Unfortunately, it did not cure the underlying tissue infection.
Chloroquine rapidly became the drug of choice the world over
and still holds that position at this writing.
By 1946, we had exhausted the supply of suitable patients
at the Atlanta prison which made it necessary to move the
project to the Federal Correctional Institution in Seagoville,
Texas. At that facility studies were carried on to determine
the effectiveness of pamaquine, isopentaquine, chlorguanide,
and several antibiotics.
In view of the favorable activity of chlorguanide,it seemed
essential that we undertake assessment of chloloroquine and
chlorguanide in the field. To implement that activity, a field
unit from the Seagoville staff was set up in Guatemala in early
1948. This study was made possible through a cooperative
arrangement with that government, the PHS, and the Pan
American Sanitary Bureau. All went well until the unsettled
conditions in that country made it necessary to terminate the
work. However, the results demonstrated clearly that each of
the drugs reduced the incidence of malaria significantly; the
greatest reduction occurred in areas under chloroquine suppression.
In 1949, those in "high places" decided that with the war
over and an excellent drug in hand, malaria was of minor importance. As a consequence, it was suggested that I might turn
my energies to a more important problem-the common cold.
I was not interested in the common cold and said so, knowing
full well that as a commissioned officer I could be ordered to
study it-I wasn't.
The Seagoville installation was closed, and I decided to
take a vacation. I had not had one since the war started except
for six weeks in the hospital nursing a bleeding ulcer in 1946,
if one can call that a vacation. We bought a new car, and the
Coatney family took off for the West Coast on a two-month
trip, hopefully without a telephone. All went well until while
in Yellowstone Park, waiting for Old Faithful to erupt, the car
radio was turned on and I learned that President Truman had
sent troops into South Korea.
It was plain that our vacation was about over because I
could see that Commander Coatney would soon be back in
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prisoner volunteer ~alaria studies again. The life. pattern ~f
Korean vivax malana was well known to me, WhICh made It
obvious that many surgical cases flown to Walter Reed Hospital in Washington, D.C., would experience attacks of malaria
about Christmas time. While those patients were in Korea they
were on weekly doses of chloroquine, but when taken out of
the area the drug would be withdrawn allowing the disease to
express itself. What was needed was a curative drug. We had
quit too soon!
There had been a few trials of primaquine, a new 8amino qUinoline , by Dr. Alf Alving at the Statesville prison
in Illinois which showed it to be four times as active and onefourth as toxic as pamaquine. There would have to be a more
exhaustive evaluation of that drug before it could be recommended to the armed services. In other words, the Atlanta
operation would have to be reactivated, which involved hospital space, a source of infected mosquitoes, and a new staff. I
could handle all but one part of that setup, namely finding a
capable physician with a research bent and willing to work
behind bars. It would be unfair to ask Dr. Cooper to come
back for he was then Chief of Medicine at the U.S. Public
Health Hospital in San Francisco. However, in desperation I
called him, mentioning that we were again at war and that I
needed him. He came and stayed five months until Dr. Al
Myatt was ready to take over. The primaquine studies in our
volunteers showed that when employed at a dosage of 15 mg
daily for 10 to 15 days, a regimen recommended by Dr. Leon
Schmidt, it cured vivax infections. This was important information but, in the absence of extensive toxicological data, it
was deemed necessary to study the tolerability of the drug in
soldiers rotated home from Korea.
That study was carried out in 1951 involving a thousand
army personnel at Fort Benning, Georgia, and at Fort Knox,
Kentucky, under my supervision and Dr. Alving, respectively.
Those tests demonstrated the overall safety of administering
a single 15-mg dose of primaquine daily for 14 days to military personnel on full duty. Following that demonstration an
o;·der was issued stating that all soldiers returning from Korea
by ship would be given 15 mg of primaquine daily for 14 days.
That was done beginning in December 1951. The navy, on the
other hand, had a shipload of marines ready to return to the
States. The order said "soldiers" and these were marines, so on
that basis they were not given primaquine. That decision was
unfortunate in one respect and extremely fortunate in another.
We had estimated that the malaria seed-rate in all returnees
from Korea would be about 20%. Among the returned soldiers,
about 280,000, the relapse rate following primaquine treatment was close to nil. However, in the marines, most of whom
went to Camp LeJuen, more than 19% came down with malaria. The navy was embarrassed, but we were elated because
the navy had unwittingly performed the crucial experiment

to prove that primaquine would cure infections of vivax
malaria.
We next turned our attention to a new type of antimalarial drug, produced by the Wellcome Laboratories in
New York, known as pyrimethamine. Therapeutic studies in
lower animals and the prisoner volunteers showed that it had
the highest activity against blood forms of the parasite of
any known antimalarial. One of the technicians in our NIH
testing laboratory told me, with a twinkle in her eyes, that
she was afraid to open a bottle of the drug in the laboratory
for fear it would cure every infection in the room. However,
resistance to pyrimethamine developed quickly against the
blood infection in avian, simian, and human malaria; more
disturbing was the fact that the resistance factor was transmitted unchanged through the mosquito. Subsequent studies
showed deleterious changes in the bone marrow and kidneys
of man. It was an excellent drug whose disadvantages outweighed its usefulness.
As a consultant to the Parke Davis Company, I made frequent trips to their home plant and always made it a point to
needle the chemists about their failure in developing a highly
effective injectable drug that would give protection over an
extended period. They seemed to shrug off that suggestion,
but in the end they developed an effective drug known as
Camolar. A single injection gave protection against a sporozoite-induced malaria in volunteers for upwards of one year.
Such results were unheard of in the management of malarial
infections. On the basis of such extraordinary results, it was
decided to test the drug in the field. At the invitation of the
Government of Pakistan, Dr. Peter Contacos and I went there
only to meet up with the problem of resistance to chlorguanide, the parent form of the drug. That coupled with the
disadvantage of distress at the site of injection caused us to
terminate the trials. Another case where many are called but
few are chosen.
I know at some time during this essay, time should be
given for a more complete account of the volunteers and their
contribution to the biology of the human malarias, to the
search for new antimalarial drugs, and to their attitude toward
participation. I shall do so now.
Those men considered themselves the elite of the prison
population and, in a sense, they were. They had been selected
first by the custodial staff and select~tl again by our medical
staff. As volunteers they were exempt from many of the
prison rules. All their illnesses, except surgery, were handled
by the project physicians, and they had the only wide-screen
color TV in the prison. To project their elitest view they designed their own patch with an embroidered MP (malaria
project) in bright yellow on a blue denim background, which
they sewed on their left sleeve above the elbow.
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On our side, we instituted a series of strict routine procedures necessary for the scientific accuracy of the study and
for 24-hour overall control of the project. The staff received
relatively few complaints concerning these procedures, because
the volunteers understood the need for them. A few objected
and considered withdrawing from the study, which they had
every right to do, but in so doing they would have to give up
their good time, their elitest status, and withstand the scorn,
or worse, of their project-mates where the maxim was: we are
all in this together. Among approximately one thousand men,
fewer than a handful withdrew.
Administration of test drugs was decided by lot. This was
fair and necessary because it prevented any semblance of
favoritism by the staff. When a man drew a number, that was
it. If a test drug was not effective, the volunteer would come
down with the disease: high fever, etc. If effective, he would
be protected. The same procedure was used when testing drugs
for therapeutic effectiveness. The men saw this as "the luck of
the draw." Once while interviewing a volunteer I asked him
why he wanted to join the project. He replied, "I have a
brother in the army and this is the only way I can fight." We
took him.
One day Dr. Cooper told me that "Jones" was having a
tough time. I went to the ward to see him. He had just gone
through a prolonged vomiting episode, and as I approached his
bed he gave me a faint smile. I asked him how things were
going. I will never forget his reply: "Doc, I wouldn't go through
this again for a million dollars, but I'll go through with it this
time if it kills me." I could only say, "Thank you. You're a
real soldier."
On another occasion I was awarding certificates to those
who had completed their six-month participation. As one
man's name was called, he stepped forward a couple of steps
and asked if he could say something. I agreed and he said,
"Please send that certificate to my mother. I don't want to
touch it. It's the only honest thing I have ever done." That
mother got the certificate and a letter from me praising her
son's participation.
I think I should include one more example for, to my
mind, it gives the attitude of the volunteer as he saw it. The
Parke Davis Company was considering setting up their own
drug-testing facility in the Florida State Prison at Raiford. I
was invited to go there as a consultant, and as I was walking
along one of the hospital corridors an inmate, who was mopping the floor, looked up and said, "Hi, Doc. Are you going to
set up a malaria project here? If you are, I want on it." My
reply was, "Thanks we may need you." That man had been a
volunteer in our Atlanta prison project, received his good time,
and was then serving time in Florida. He was a walking advertisement for our volunteer program.

Up to 1960 I had worked mainly in two fields: (1) the
blood parasites of birds, including malaria; and (2) the biology
and chemotherapy of the human malarias. Then came a decided change. On 5 May I was sitting at my desk at the NIH
when a call came through from Dr. Don Eyles, in charge of
our Memphis laboratory, and I heard him say, "Bob, I have
monkey malaria." I was incredulous. I told him not to take
chloroquine until we were sure. He replied that he expected
I would say that so he had taken the drug before he called.
In other words, he was the one suffering the chills and fevernot I. Prior to taking the drug, he had drawn 20 cc of his own
blood and injected a portion of it into an uninfected monkey.
I asked him to send the remainder to the Atlanta prison for
transfer to volunteers. That was done, and in a few days the
recipient monkey and each of the volunteers came down with
malaria. Plasmodium cynomolgi of monkeys would grow in
man and produce disease. Malariologists, including myself,
knew that monkeys harbored malaria infections, but erroneously we thought malaria in the monkey was for monkeys
and malaria in man was for people. That tenet would have to
be discarded. The greater question was: is monkey malaria a
true zoonosis, an anthroponosis, or both?
At the time of the Eyles accidental infection by mosquito
bite, three species of simian malaria were known from Malaya.
The species responsible for his infection had been isolated from
a monkey in northeastern Malaya. Under the circumstances
it seemed worthwhile to go there to study the simian malarias.
When I presented the opportunity to Eyles, he was enthusiastic and went there in August with a small staff. He had three
main objectives: (1) to study malaria in the indigenous monkeys, (2) to determine their natural vectors, and (3) to investigate the possibility of the natural transmission of monkey
malaria to man.
The productivity of the Eyles group was phenomenal.
During less than four years they identified two dozen vectors
of simian malaria and described five new species (one was
named for me). When those are added to the three already
known, Malaya is surely the birthplace of malaria and, I like
to think, maybe the Biblical Garden of Eden. Dr. Eyles's
untimely death cut short a brilliant career and eventually reo
sulted in our closing the laboratory.
The simian malaria program at the Atlanta prison was in.
the charge of Dr. Peter Contacos, and as the Malayan and other
species of simian malaria became available they were sent to
him for possible transfer to prison volunteers. Con tacos established five simian species in man and carefully described their
parasitology and clinical manifestations in studies involving
some 225 volunteers.
At this juncture I had spent some twenty years in charge
of studies involving human and simian malarias, their biology,
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and treatment. The human hosts for these studies were prison
volunteers, as mentioned earlier, who willingly accepted the
rigors of the disease and the uncertainty of the test drugs. Their
antisocial conduct had landed these men behind bars, but they
proved to have honor too. If they made a commitment, they
kept it. I can certify that the PHS kept its commitment to
them. I was privileged to work with these men longer than any
staff member. It was an experience of a lifetime, and I cherish
the opportunity.
Most of what I have dealt with here has had to do with
the evaluation of new drugs in man and with the possible
threat of simian malaria as a zoonosis, but I am not unmindful
of the work carried on in our laboratories at the NIH, Columbia, South Carolina, and Memphis, Tennessee, in support of
those studies: the initial testing of potentially effective drugs
against blood- and sporozoite-induced P. gallinaceum infections
in day-old chicks, a program that embraced more than 2,000
compounds; the intensive study of all aspects of P. gallanaceum
infections in young chicks; Miss Helen Trembly's management
of the insectary where countless thousands of mosquitoes
were raised for transmission of malarias to the chicks and to
humans; the basic studies on drug metabolism by Drs. Howard
Bond and John Sherman; Dr. Joseph Greenberg's discovery of
synergism in antimalarials; and Dr. Joe Held's technique for
locating malarial exoerythrocytic bodies in the liver of infected
monkeys. These highlights, plus others too numerous to mention, came about with me, in terms of the game of football, as
coach and quarterback. However, let it not be forgotten that it
was the members of a remarkable staff who carried the ball. My
philosophy was, and is, that team research hinges on finding
someone else to do what I want done because he wants to do it.
In 1960 I was named chief of the Laboratory of Parasite
Chemotherapy and continued in that capacity until terminated
by the law that states that commissioned officers of the PHS
must retire at age 64. Tempus vitam regit. As a consequence,
Captain Coatney became a civilian following his retirement on
31 May 1966.
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Epilogue
Prior to my retirement I had been invited to accept a

position as Professor of Pharmacology at the Louisiana State
University School of Medicine in New Orleans and had
accepted. My teaching schedule allowed ample time for research, and upon inquiry I learned that several chimpanzees at
the Delta Regional Primate Center, at nearby Covington,
Louisiana, were available for studies involving malaria. The
availability of these animals gave an opportunity to study
Plasmodium schwe tzi, an ape parasite, which had eluded us
earlier. Through a series of fortunate circumstances two
chimps were infected by the inoculation of infected blood
and, in due time, through the cooperation of Dr. Contacos,
then in charge of myoid Atlanta project, prisoner volunteers
were infected through the bites of infected mosquitoes. The
malaria parasite which infected the volunteers was not like P.
schwetzi, as expected, but like P. ovale which we knew quite
well as a tertian malaria parasite of man. When the parasite
was transferred back to an uninfected chimpanzee the resulting infection was P. schwetzi again. At that point I decided
to let some other investigator unravel the P. schwetzi-P. ovale
riddle. Those confusing results remind us that when we ask
questions of nature the answer may be pleasant, shocking, or
wrapped in an enigma.
After three enjoyable and scientifically profitable years in
New Orleans, I decided to retire a second time. We moved to
Atlanta, Georgia, a beautiful city with a mild climate, many
old friends, and former colleagues.
During a luncheon with a group of former staff members, the question was raised about finishing the book on
the primate malarias begun in 1966 and abandoned. Drs.
William Collins, McWilson Warren, and Peter Contacos agreed
to collaborate if I would assume overall responsibility. We
all got to work and The Primate Malarias appeared in 1971.
Our aim was to present a comprehensive treatment of all the
primate malarias. If that aim was realized, and I think it was,
it is an important addition to the literature of the primate
malarias.
Now I am a true retiree-mowing the lawn, getting
reacquainted with my malaria-related stamp collection, and
enjoying an introduction to historical horology to the extent
of collecting and writing about early American clocks. Retirement is wonderful if one can get used to it.

